论文部分内容阅读
目的研究血脂康对心绞痛合并高脂血症患者的降脂作用及对血粘度与血小板聚集度影响。方法 6 4例心绞痛合并高脂血症随机分为血脂康组和甘糖酯对照组 ,分别口服血脂康 1 .2 g/ d或甘糖酯 2 0 0 mg/ d,连服 8周 ,治疗前后测定血脂谱 ,血粘度和血小板聚集度。结果 1服血脂康和甘糖酯 8周后 ,TC、TG和 L DL -C明显下降 (P均 <0 .0 1 ) ,HDL -C明显升高 (P均 <0 .0 1 )。血脂康降低 TG的作用弱于甘糖酯 (P<0 .0 5) ,而降低 TC、L DL -C和升高 HDL -C的作用与甘糖酯比较差异无显著性 (P均 >0 .0 5)。 2血脂康和甘糖酯均可明显降低血粘度和血小板聚集度 (P均 <0 .0 1 )两者比较无显著性差异 (P均 >0 .0 5)。结论血脂康具有较好的降脂作用 ,其降低TC、L DL -C、血粘度、血小板聚集度和升高 HDL -C的作用与甘糖酯相近 ,其降低 TG的作用弱于甘糖酯。
Objective To study the effects of Xuezhikang on lipid-lowering effect and blood viscosity and platelet aggregation in patients with angina pectoris and hyperlipidemia. Methods Sixty-four patients with angina pectoris and hyperlipidemia were randomly divided into Xuezhikang group and control group, respectively, oral Xuezhikang 1.2 g / d or 200 mg / d sugar ester, for 8 weeks, treatment Before and after the determination of blood lipid profile, blood viscosity and platelet aggregation. Results After 8 weeks of treatment, the levels of TC, TG and L DL-C decreased significantly (all P <0.01) and HDL-C significantly increased (all P <0.01). Xuezhikang reduced the effect of TG less than that of the sugar ester (P <0.05), while the effects of lowering TC, L DL -C and increasing HDL-C were not significantly different from those of the sugar ester (P> 0.05) .0 5). 2 Xuezhikang and sugar ester can significantly reduce the blood viscosity and platelet aggregation (P <0.01) there was no significant difference between the two (P all> 0.05). Conclusion Xuezhikang has a good lipid-lowering effect, and its role in reducing TC, L DL-C, blood viscosity, platelet aggregation and HDL-C increase is similar to that of the sugar ester. The effect of reducing TG is weaker than that of the sugar ester .